License from Synaffix focuses on bispecific ADCs This close collaboration between ABL Bio and Synaffix provides optimal conditions to accelerate research and development of resulting next-generation bioconjugates AMSTERDAM, THE NETHERLANDS, 13 September 2023 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibodydrug conjugates (ADCs) with […]
Positive results from testing SPOR-COV in several COVID-19 and influenza research models support potential as prophylactic nasal spray Toxicology studies support safety profile Manufacturing process established Manufacturing and regional licensing agreement signed with HURO Biotech JSC for Vietnam Phase 1 clinical studies completed successfully in Vietnam by HURO Retail product based on SPOR COV technology […]
AMSTERDAM, THE NETHERLANDS, 5 January 2023 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), today announced the signing of a licensing agreement with Amgen to develop next generation ADCs. Amgen will gain access to Synaffix’s antibody conjugation technology platforms comprising GlycoConnect™, HydraSpace™ and select […]
